title: [Potential new antidiabetics for the next decade].
abstract: In the next 10 years, major changes in the pharmacotherapy of diabetes can be expected. Both the currently used groups of drugs classified as dipeptidyl-peptidase IV blockers (gliptins) and so-called incretin mimetics (including both natural substances and incretin analogues) will be significantly expanded by up to ten new drugs. In addition, other completely new groups of drugs that act, for instance, via the hepatal mechanism or by influencing the metabolism of steroids will appear. Blocking the absorption of glucose in renal tubules by gliflozines seems to be very promising. In the treatment of diabetes complications, the inhibition of protein kinase C will probably mostly be applied. So-called insulinotropic peptides will very likely be applied by injection and substances reducing insulin resistance as well as new types of substances influencing PPAR nuclear receptors will be administered. In diabetology, antibodies against receptors will be used, too. However, modern pharmacotherapy will undoubtedly come up against the principles of so-called metabolic surgery and other successful technological procedures.
authors.affiliation: III. interní klinika 1. lékarské fakulty UK a VFN Praha. svacinas@lf1.cuni.cz
authors.forename: S
authors.initials: S
authors.lastname: Svacina
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D054795:Incretins / Q000819:agonists / Q000627:therapeutic use; D051247:Sodium-Glucose Transport Proteins / Q000037:antagonists & inhibitors
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D054795:Incretins; D051247:Sodium-Glucose Transport Proteins